272 Capital LP Acquires Shares of 50,000 Certara, Inc. (NASDAQ:CERT)

272 Capital LP bought a new position in Certara, Inc. (NASDAQ:CERT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company’s stock, valued at approximately $586,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Blue Trust Inc. purchased a new stake in shares of Certara during the second quarter worth $26,000. Innealta Capital LLC purchased a new stake in Certara during the 2nd quarter worth about $36,000. KBC Group NV boosted its stake in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new position in Certara during the 2nd quarter valued at about $152,000. Finally, Algert Global LLC bought a new stake in shares of Certara during the second quarter valued at about $156,000. Institutional investors own 73.96% of the company’s stock.

Certara Trading Up 3.0 %

Shares of NASDAQ:CERT opened at $11.71 on Friday. The company’s fifty day moving average price is $10.84 and its 200-day moving average price is $12.70. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 earnings per share. As a group, analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

CERT has been the subject of a number of analyst reports. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Finally, Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.92.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.39% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.